About this trial
This study looks at how well TAR-210 works compared to standard chemotherapy for bladder cancer. The focus is on patients with intermediate-risk non-muscle invasive bladder cancer. The goal is to see which treatment helps keep the cancer from coming back longer.
The trial is registered under the ID NCT06319820. This is a Phase 3 trial, which means it is looking at how well the treatment works and how safe it is. About 641 people are expected to join, and it is regulated by the FDA.
Who can join
Adults aged 18 and older can join this study. Both men and women are welcome. Participants must have a confirmed diagnosis of a specific type of bladder cancer and meet certain health criteria. The study team will check who is eligible before enrollment.
Condition
Non-Muscle Invasive Bladder Neoplasms
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will be divided into two main groups by chance. One group will receive TAR-210 inserted into the bladder over about a year. The other group will receive standard chemotherapy with either mitomycin C or gemcitabine. There is also a substudy with similar groups for those who meet specific criteria.
Where
This trial is running at 38 locations in the United States.
Arkansas Urology
Little Rock, Arkansas
Associated Medical Professionals of Ny
Syracuse, New York
Associated Urologists of North Carolina
Raleigh, North Carolina
Brigham And Women's Hospital
Boston, Massachusetts
Cancer Institute Of New Jersey
New Brunswick, New Jersey
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Chesapeake Urology Research Associates
Hanover, Maryland
Colorado Clinical Research
Lakewood, Colorado
The first 8 of 38 sites are listed here. The registry record has the full list.